PTO/SB/08a (08-03)

Approved for use through 07/31/2006. 0MB 0551-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE espond to a collection of information unless it displays a valid OMB control number. Under the Paperwork Reduction Act of 1995, no person
Substitute for form 1449A/PTO Complete If Known FIRST SUPPLEMENTAL 10/551 054 §371 (c) Date: September 23, 2005 INFORMATION DISCLOSURE Named Inventor BACHMANN, Martin F. STATEMENT BY APPLICANT MOSHER, Mary (Use as many sheets as necessary) οf 1700,0590000/BJD/WBC Sheet

Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant Passages	
Initials*	No.1	Number-Kind Code ^{2 (f Known)}	MM-DD-YYYY	Cited Document	or Relevant Figures Appear	
	AC3	US- 5,962,636	10/05/1999	Bachmaier et al.		
	AD3	US- 2001/0044416 A1	11/22/2001	McCluskie et al.		
	AE3	US- 2003/0060440 A1	03/27/2003	Klinman et al.		
	AF3	US- 2003/0087848 A1	05/08/2003	Bratzler et al.		
	AG3	US- 6,949,520 B1	09/27/2005	Hartmann et al.		
	AH3	US- 2005/0169888 A1	08/04/2005	Hartmann et al.		
-	Al3	US- 2006/0286070 A1	12/21/2006	Hartmann et al.		

		FC	REIGN PATENT DOC	UMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ⁴ Kind Code ⁵ (in known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Retevant Passages or Relevant Figures Appear	Ţ
	A09	EP 0 468 520 A2	01/29/1992	Tokunaga et al.		
	AP9	WO 92/11291 A1	07/09/1992	Van Wijnendale et al.		
	AL10	WO 94/02499 A1	02/03/1994	Padmapriya et al.		
	AM10	WO 95/26204 A1	10/05/1995	Hutcherson et al.	T	
	AN10	WO 96/02555 A1	02/01/1996	Krieg		
	AO10	EP 0 772 619 B1	05/14/1997	Krieg et al.		

Examiner Signature	Date		_
/Mary Mosher/	Considered	04/07/2008	

EXAMINES hast intersect considered, whether on not classes in a considered process. In the considered process of the considered process of the considered process of the considered process of the considered process. The considered process of the conside

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Rev. 11-03-03 svb

PTO:SB/08a (06-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Palent and Trademark Office: U.S. DEPARTNENT OF COMMERCE
equired to a collection of information unless it displays a valied OMB control number.
Complete If Knowlets

C Under the Paperwork Reduction Act of 1995, no persons are Substitute for form 1449A/PTO Complete If Known Application Number 10/551.054 Filing Date §371 (c) Date: September 23, 2005 INFORMATION DISCLOSURE First Named Inventor BACHMANN, Martin F STATEMENT BY APPLICANT Art Unit Examiner Name (Use as many sheets as necessary) MOSHER, Mary Attorney Docket Number 1700.0590000/BJD/WBC Sheet

Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (If Known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures
					Appear
			ı		
	1	ì			
		-	_		
			_		
		1			
	1				
	1			-	
	+	1		 	

	FOREIGN PATENT DOCUMENTS										
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ⁴ Kind Code ⁵ (in known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴					
	AP10	WO 97/28259 A1	08/07/1997	Carson							
	AL11	WO 98/18810 A1	05/07/1998	Krieg et al.							
	AM11	EP 0 855 184 A1	07/29/1998	Lipford et al.							
	AN11	WO 98/33517 A1	08/06/1998	Foster et al.							
	AO11	WO 98/52581 A1	11/26/1998	Davis et al.							
	AP11	WO 98/55495 A2	12/10/1998	Schwartz et al.							

/Mary Mosher/		Date Considered	04/07/2008	Ī
*EXAMINER: Initial if reference consider	ed, whether or not citation is in conformance with M PEP 609. Draw line through citat	on if not in conformance	e and not considered. Include copy of this	-1

(orm with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uscipi.gov/en/HPP901.04. For Japanese patent document, be the document, by the two-letter code (WIPPO Standard ST.3). For Japanese patent document, be indication of the year of the reging of the Engeror must precede the serial number of the patent document, "And of document by the appropriate symbols as indicated on the document under WIPPO Standard ST.1 61 possible." Applicant is to place a drieck manner. "Exter Office that issued the document, by the No-sterior code (WHV) Standard 81.3). To abpointed patient documents, the Modition of the year of the rings of the Engineer must proceed the respect to the rings of the Engineer. Application is not added in the Comment under WHO Standard 8.7 List (possible 5). Application is to piotate a detect many her Engilative require part Transaction is indicated in the document under WHO Standard 8.7 List (possible 5). Application is to piotate a detect many her Engilative require part Transaction is intelligent to the Standard Standard

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Rev. 11-03-03 svb

PTO/SB/08a (06-03)
Approved for use through 07/31/2006, OMB 0853-0031
U.S. Patent and Traderrark Office: U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it displays a valid OMB control number. Under the Paperwork Reduction Act of 1995, no person Substitute for form 1449A/PTO mplete If Known Application Number 10/551 054 Filing Date §371 (c) Date: September 23, 2005 INFORMATION DISCLOSURE First Named Inventor BACHMANN, Martin F. STATEMENT BY APPLICANT Art Unit Fyaminer Name MOSHER, Mary (Use as many sheets as necessary) Attorney Docket 1700.0590000/BJD/WBC Sheet 3

			Trained		
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (B Known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
				~~~	
	_				
	1				

Examiner Initials*	Cite No.'	Foreign Patent Document Country Code ⁴ Kind Code ⁵ (in known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ^d
	AL12	WO 99/11275 A2	03/11/1999	Ray		
	AM12	WO 99/29723 A1	06/17/1999	Hall		
	AN12	WO 99/51259 A2	10/14/1999	Krieg et al.		
	AO12	WO 00/06588 A1	02/10/2000	Krieg		
	AP12	WO 00/14217 A2	03/16/2000	Wagner et al.		
	AL13	WO 00/23955 A1	04/27/2000	Schiller et al.		

Examiner Signature /Mary Mosher/	Date Considered	04/07/2008	

EX.UMINER inside inference considered, whether or not custom is in conformance with M PEP-809. Dow line through claims in rind in conformance and not considered, british copy of this final inference considered, whether or not custom is in conformance with M PEP-809. Dow line through claims in rind in conformance and not considered, british copy of the final inference considered, british copy of the final inference considered, british copy of the final inference considered considered in the conformation of the part of the region of the final inference considered considered in the considered in the considered in the considered considered in the considered

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

Complete If Known

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet

(Use as many sheets as necessary)

Application Number 10/551,054 Filing Date §371 (c) Date: September 23, 2005 First Named Inventor BACHMANN, Martin F Art Unit 1648 Lyammar Nama MOSHER, Mary Allomey Dockel Number

1700.0590000/BJD/WBC

Sileet	- 4	1 0		1100.00000	10/202/11/20
Examiner Cite Initials* No.1		Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ^{2 (If Known)}		Once December	Appear
	-				
	1				
	+				+
	1				
	1				
	+				
	1	1	1	1	1

		Foreign Patent Document	IGN PATENT DOCUM		Pages, Columns.	
Examiner Initials*	Cite No.1	Country Code ⁴ Kind Code ⁵ (in known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	AM13	WO 02/10416 A1	02/07/2002	Gowans et al.		
	AN13	WO 02/056905 A2	07/25/2002	Renner et al.		
	AN13	WO 03/030656 A2	04/17/2003	Babiuk et al.		
	AP13	WO 03/040308 A2	05/15/2003	Klinman et al.		
	AL14	WO 03/045431 A2	06/05/2003	Vicari et al.		
	AM14	WO2005/014110 A1	02/17/2005	Bachmann et al.		

Examiner Signature Sher/ Date 04/07/2008 Considered

EXAMINER Initial if inference considered, whether or not clastion is in conformance with M FEP 600. Date line through obtained if not in conformance and not considered. Include copy of the SEAMINER Initial if inference considered, whether or not classification is one of the company of the SEAMINER INITIAL INI

Approved for use through 06/30/2006, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	substitute for form 1449B/PTO			Complete If Known		
		SUPPLE	MENTAL	Application Number	10/551,054	
INFORMATION DISCLOSURE				Filing Date	§371 (c) Date: September 23, 2005	
	STATEMENT BY APPLICANT		First Named Inventor	BACHMANN, Martin F.		
	(Lien a	s many sheets as r	necessary)	Art Unit	1648	
	(0.00	a many and do i		Examiner Name	MOSHER, Mary	
Sheet	1	of	6	Attorney Docket Number	1700.0590000/BJD/WBC	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	NPL84	Ballas, Z.K., et al., "Induction of NK Activity in Murine and Human Cells by CpG Motifs in Oligodeoxynucleotides and Bacterial DNA," J Immunol 157(5):1840-5, The American Association of Immunologists, Inc. (1996)	
	NPL85	Bartholomé, E.J., et al., "IFN-β Interferes with the Differentiation of Dendritic Cells from Peripheral Blood Mononuclear Cells: Selective Inhibition of CD40-Dependent Interleukin- 12 Secretion," J Interferon Cytokine Res 19(5):471-8, Mary Ann Liebert, Inc. (1999)	
	NPL86	Blackwell, S.E., and Krieg, A.M., "CpG-A-Induced Monocyte IFN-y-Inducible Protein-10 Production is Regulated by Plasmacytoid Dendritic Cell-derived IFN-a," <i>J Immunol.</i> 170(8):4061-8, The American Association of Immunologists Inc. (April 2003)	
	NPL87	Branda, R.F., et al., "Amplification of antibody production by phosphorothioate oligodeoxynucleotides," J Lab Clin Med 128(3):329-38, Mosby-Year Book Inc. (1996)	
	NPL88	Cella, M., et al., "Maturation, activation, and protection of dendritic cells induced by double-stranded RNA, " J Exp Med 189(5):821-9, The Rockefeller University Press (1999)	
	NPL89	Cella, M., et al., "Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon," Nat Med 5(8):919-23, Nature America Inc. (1999)	
	NPL90	Clark, B., et al., "Immunity against both polyomavirus VP1 and a transgene product induced following intransaal delivery of VP1 pseudocapsid-DNA complexes," J. Gen. V/rol. 82:2791-2797, Society for General Microbiology (2001)	
	NPL91	Dalpke, A.H., et al., "Phosphodiester CpC oligonucleotides as adjuvants: polyguanosine runs enhance cellular uplake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo," Immunology 106(1):102-12, Blackwell Science Ltd. (May 2002)	
	NPL92	Goeckeritz, B.E., et al., "Multivalent cross-linking of membrane ig sensitizes murine B cells to a broader spectrum of CpG-containing oligodeoxynucleotide moltis, including their methylated counterparts, for stimulation of proliferation and Ig secretion," Int Immunol 11(10):1693-700, Oxford University Press (1999)	
	NPL93	Halperin, S.A., et al., "A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant," Vaccine 21(19-20):2461-7, Elsevier Science Ltd. (June 2003)	

Examiner Signature /Mary Mosher/	Date Considered	04/07/2008	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 US.C. 122 and 37 CFR 1.14. This collection is estimated to take hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to Chel information Officer, U.S. Department of Commence, P.O. Box 1430, Alexandria, VA.2231-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

				C	omplete If Known
Substitute fe	or form 1449	в/РТО		Application Number	10/551,054
INF	ORMA	ATION DI	SCLOSURE	Filing Date	§371 (c) Date: September 23, 2005
ST	ATEM	ENT BY	APPLICANT	First Named Inventor	BACHMANN, Martin F.
	(Use a	s many sheets as	necessary)	Art Unit	1848
				Examiner Name	MOSHER, Mary
Sheet	2	of	6	Attorney Docket Number	1700.0590000/BJD/WBC

## NON PATENT LITERATURE DOCUMENTS Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Examiner T2 (book, magazine, journal, senal, symposium, catalog, etc.), date page(s), volume-issue number(s), Initials publisher, city and/or country where published Halpern, M.D., et al., "Bacterial DNA Induces Murine Interferon-y Production by NPL94 Stimulation of Interleukin-12 and Tumor Necrosis Factor-a," Cell Immunol 167(1):72-8, Academic Press Inc. (1996) Hartmann, G., et al., "CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells," Proc Natl Acad Sci U S A 96(16):9305-10, National Academy of NPL95 Sciences (1999) Heath, A.W., "Cytokines and the Rational Choice of Immunological Adjuvants," Cancer NPL96 Biother 9(1):1-6, Mary Ann Liebert, Inc., Publishers (1994) Iho, S., et al., "Oligodeoxynucleotides Containing Palindrome Sequences with Internal 5'-CpG-3' Act Directly on Human NK and Activated T Cells to Induce IFN-y Production In NPL97 Vitro," J Immunol 163(7):3642-52, The American Association of Immunologists (1999) loannou, X.P., et al., "CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein," Vaccine 21(1-2):127-37, Elsevier Science NPL98 (November 2002) Kerkmann, M., et al., "Activation with CpG-A and CpG-B Oligonucleotides Reveals Two Distinct Regulatory Pathways of Type I IFN Synthesis In Human Plasmacytoid Dendritic NPL99 Cells," J Immunol. 170(9):4465-74, The American Association of Immunologists Inc (May 2003) Kline, J.N., et al., "Modulation of Airway Inflammation by CpG Oligodeoxynucleotides in a NPL100 Murine Model of Asthma." J Immunol 160(6):2555-9. The American Association of Immunologists (1998) Kline, J.N., et al., "Treatment of established asthma in a murine model using CpG NPL101 oligodeoxynucleotides," Am J Physiol Lung Cell Mol Physiol 283(1):L170-9, American Physiological Society (July 2002) Klinman, D.M., "Immunotherapeutic Uses of CpG Oligodeoxynucleotides," Nat Rev NPL102 Immunol 4(4):249-58, Nature Publishing Group (April 2004) Klinman, D.M., et al., "CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon y." Proc Natl Acad Sci U S A NPL103 93(7):2879-83. National Academy of Sciences (1996)

L	CO(1).2010 CO; Mademary loadering of Colonico (10)		
Examiner Signature /Mary Mosher/		Date Considered	04/07/2008
L		L	

"EXAMINER: Initial if refrence considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional). "Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file unit by the LIPTO by process) an application. Confidentially is governed by 3.5 U.S. C. 122 and 3.7 CFR 1.14. This collection is selfund to take 2 hours to complete, including anthering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time by or might to complete this form and/or suggestions for reducing this burder, benefit when the Chief Information Officer, U.S. Palent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, V.A. 22313-1450, DVSNOP EESO PG COMPLETED FORMS TO THIS ADDRESS. SEN DTC. Commissioner for Parents, P.O. Box 1450, Alexandria, V.A. 22313-1450, DVSNOP EESO PG COMPLETED FORMS TO THIS ADDRESS. SEN DTC. Commissioner for Parents, P.O. Box 1450, Alexandria, V.A. 22313-1450, DVSNOP EESO PG COMPLETED FORMS TO THIS ADDRESS. SEN DTC. Commissioner for Parents, P.O. Box 1450, Alexandria, V.A. 22313-1450, DVSNOP EESO PG COMPLETED FORMS TO THIS ADDRESS. SEN DTC. Commissioner for Parents, P.O. Box 1450, Alexandria, V.A. 22313-1450, DVSNOP EESO PG COMPLETED FORMS TO THIS ADDRESS. SEN DTC. Commissioner for Parents, P.O. Box 1450, Alexandria, V.A. 22313-1450, DVSNOP EESO PG COMPLETED FORMS TO THIS ADDRESS. SEN DTC. Commissioner for Parents, P.O. Box 1450, Alexandria, V.A. 22313-1450, DVSNOP EESO PG COMPLETED FORMS TO THIS ADDRESS. SEN DTC. Commissioner for Parents, P.O. Box 1450, Alexandria, V.A. 22313-1450, DVSNOP EESO PG COMPLETED FORMS TO THIS ADDRESS. SEN DTC. Commissioner for Parents, P.O. Box 1450, Alexandria, V.A. 22313-1450, DVSNOP EESO PG COMPLETED FORMS TO THE ADDRESS. SEN DTC. Commissioner for Parents, P.O. Box 1450, Alexandria, V.A. 22313-1450, DVSNOP EESO PG COMPLETED FORMS TO THE ADDRESS. SEN DTC. Commissioner for Parents, P.O. Box 1450, Alexandria, V.A. 22313-1450, DVSNOP EESO PG COMPLETED FORMS TO THE ADDRESS.

PTO/SB/08b (08-03)
Approved for use through 08/30/2006. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Complete If Known Substitute for form 1449B/PTO Application Number 10/551.054 INFORMATION DISCLOSURE Filing Date §371 (c) Date: September 23, 2005 STATEMENT BY APPLICANT First Named Inventor BACHMANN, Martin F. 1648 (Use as many sheets as necessary) Art Unit MOSHER, Mary Examiner Name 6 Sheet 3 of Attorney Docket Number 1700.0590000/BJD/WBC

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ³	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(e), volume-issue number(e), publisher, city and/or country where published	Τ²
	NPL104	Klinman, D.M., et al., "CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques," Vaccine 22(21-22):2881-6, Elsevier Ltd. (July 2004)	
	NPL105	Krieg, A.M., "CpG Motifs in Bacterial DNA and Their Immune Effects," Annu Rev Immunol 20:709-60, Annual Reviews (April 2002)	
	NPL106	Krieg, A.M., "Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides," <i>Biochim Biophys Acta</i> 1489(1):107-16, Elsevier Science (1999)	
	NPL107	Krieg, A.M. and Davis, H.L., "Enhancing vaccines with immune stimulatory CpG DNA," Curr Opin Mol Ther 3(1):15-24, Thomson Scientific (2001)	
	NPL108	Krieg, A.M., et al., "CpG motifs in bacterial DNA trigger direct B-cell activation," Nature 374(6522):546-9, Nature Publishing Group (1995)	
	NPL109	Krieg, A.M., et al., "Oligodeoxynucleotide Modifications Determine the Magnitude of B Cell Stimulation by CpG Motifs," Antisens & Nucleic Acid Drug Dev 6(2):133-9, Mary Ann Liebert, Inc. (1996)	
	NPL110	Krug, A., et al., "CpG-A Oligonucleotides Induce a Monocyte-Derived Dendritic Cell-Like Phenotype that Preferentially Activates CD8 T Cells," J Immunol. 170(7):3468-77, The American Association of Immunologists, Inc. (April 2003)	
	NPL111	Lee, S.W., et al., "Effects of a Hexameric Deoxyriboguanosine Run Conjugation into CpG Oligodeoxynucleotides on Their Immunostimulatory Potentials," <i>J Immunol</i> 165(7):3631-9, The American Association of Immunologists (2000)	
	NPL112	Leibl, H., et al., "Adjuvant/carrier activity of inactivated tick-borne encephalitis virus," Vaccine 16(4):340-5, Elsevier Science Ltd. (1998)	
	NPL113	Liu, H.M., et al., "Immunostimulatory CpG Oligodeoxynucleotides Enhance the Immune Response to Vaccine Strategies Involving Granulocyte-Macrophage Colony-Stimulating Factor," Blood 92(10):3730-6. The American Society of Hematology (1998)	

	Examiner Signature /Mary Mosher/		Date Considered	04/07/2008
ľ	*EXAMINER: Initial if reference	considered, whether or not citation is in conformance with M PEP 609	. Draw line through cits	ation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (potional).

²Applicant's unique citation designation number (potional).

²Applicant's unique citation designation number (potional).

This collection of information is required by 37 CFR 1.97 and 1.96. The information is required to obtain or retained a benefit by the public which is to file and by the USPTO to process) an application. Confidentially is governed by 35 U.S. C. 122 and 37 CFR 1.17 ins collection is either to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vay depending upon the individual case, and you comments on the amount of time by on require to complete this form and/or suggestations for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it displays a valid OMB control number.

				С	omplete If Known
substitute for form 1449B/PTO				Application Number	10/551,054
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			ISCLOSURE	Filing Date	§371 (c) Date: September 23, 2005
			APPLICANT	First Named Inventor	BACHMANN, Martin F.
	(Use as n	nany sheets a	s necessary)	Art Unit	1648
				Examiner Name	MOSHER, Mary
heet	4	of	6	Attorney Docket Number	1700,0590000/BJD/WBC

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (whon appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, citly and/or country where published	T²
	NPL114	Mahon, B.P., et al., "The Rational Design of Vaccine Adjuvants for Mucosal and Neonatal Immunization," Curr Med Chem 8(9):1057-75, Bentham Science Publishers (2001)	
	NPL115	Pisetsky, D.S. and Reich, C.F., "Stimulation of Murine Lymphocyte Proliferation by a Phosphorothioate Oligonucleotide with Antisense Activity for Herpes Simplex Virus," <i>Life</i> <i>Sci</i> 54(2):101-7, Pergamon Press (1994)	
	NPL116	Putney, S.D., et al. "Enhanced Anti-Tumor Effects with Microencapsulated c-myc Antisense Oligonucleotide," Antisense Nucleic Acid Drug Dev. 9:451-8, Mary Ann Liebert Inc. (1999)	
	NPL117	Raz, E., "Introduction: gene vaccination, current concepts and future directions," Springer Semin Immunopathol 19(2):131-7, Springer-Verlag (1997)	
	NPL118	Raz, E., et al., "Preferential induction of a Th ₁ immune response and inhibition of specific lgE antibody formation by plasmid DNA immunization," <i>Proc Natl Acad Sci USA</i> 93(10):5141-5, National Academy of Sciences (1996)	
	NPL119	Sato, Y., et al.," Immunostimulatory DNA Sequences Necessary for Effective Intradermal Gene Immunization," Science 273(5273):352-4, American Association for the Advancement of Science (1996)	
	NPL120	Schwarz, K., et al., "Role of Toll-Like receptors in costimulating cytotoxic T cell responses," Eur. J. Immunol. 33:1465-70, WILEY-VCH Verlag (June 2003)	
	NPL121	Semple, S.C., et al., "Lipid-Based Formulations of Antisense Oligonucleotides for Systemic Delivery Applications," Methods Enzymol. 313:322-41, Academic Press (2000)	
	NPL122	Siegal, F.P., et al., "The Nature of the Principal Type 1 Interferon-Producing Cells in Human Blood," Science 284(5421):1835-7, American Association for the Advancement of Science (1999)	
	NPL123	Takauji, R., et al., "CpG-DNA-induced IFN-e production involves p38 MAPK-dependent STAT1 phosphorylation in human plasmacyloid dendritic cell precursors," J. Leukoc. Biol. 72:1011-1019, Wiley-Liss (November 2002)	

*EXAMINER: Initial if reference considere		

Considered

04/07/2008

Examiner Signature Mosher/

and not considered, include copy of this form with next communication to applicant.

Applicant's unique diation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR + 97 and 1.98. The information is required to obtain or retain a benefit by the public which is to find only the IUSPTO to process) an application. Confidentially is governed by \$1.8.C. 1.02 and \$7.CFR | 1.41 This collection is scient to label 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time by on require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Var 22313-1450, D. SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patents, P.O. Box 4450, Alexandria, Va.22313-1450.

PTO/SB/08b (08-03) Approved for use through 06/30/2006, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1700.0590000/BJD/WBC

Under	the Paperwo	rk Reduction Act	of 1995, no persons are required		ation unless it displays a valid OMB control number.	
	or form 1449E	WDTO.		Complete If Known		
Substitute it	or 101111 14491	3/210		Application Number	10/551,054	
INFORMATION DISCLOSURE			SCLOSURE	Filing Date	§371 (c) Date: September 23, 2005	
STATEMENT BY APPLICANT			APPLICANT	First Named Inventor	BACHMANN, Martin F.	
	(Use a	s many sheets as	necessary)	Art Unit	1648	
				Examiner Name	MOSHER, Mary	
Sheet	5	of	6	Attorney Docket		

Number

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (took, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, (ity and/or country where published	T ²		
	NPL124	Uhlmann, E. and Vollmer, J., "Recent advances in the development of immunostimulatory oligonulcetides," <i>Curr Opin Drug Discov Devel</i> 6(2):204-17, Thomson Scientific (March 2003)			
	NPL125	Van Ojik, H., et al., "Phase I/II study with CpG 7909 as adjuvant to vaccination with MAGE-3 protein in patients with MAGE-3 positive tumors," Ann. Oncol. 13:157-158, Abstract No. 5790, Oxford University Press (October 2002)			
	NPL126	Verthelyi, D., et al., "CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques," AIDS 18(7):1003-8, Lippincott Williams & Wilkins (April 2004)			
	NPL127	Verthelyi, D., et al., "Human Peripheral Blood Cells Differentially Recognize and Respond to Two Distinct OPG Motifs," J Immunol 168(4):2372-7, The American Association of Immunologists (2001)			
	NPL128	Vollmer, J., et al., "Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities," Eur. J. Immunol. 34:251-262, WILEY-VCH Verlag (January 2004)			
	NPL129	Vrtala, S., et al., "immunization with Purified Natural and Recombinant Allergens Induces Mouse IgG1 Antibodies That Recognize Similar Epitopes as Human IgE and Inhibit the Human IgE-Allergen Interaction and Allergen-Induced Basophil Degranulation," J. Immunol. 16:06:317-6144, The American Association of Immunologists, Inc. (1998)			
	NPL130	Weiner, G., "Declaration of Dr. George Weiner Under 37 CFR §1.32," submitted in support of US Application No. 09/286,098, 9 pages (2000)			
	NPL131	Weiner, G.J., et al., "Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization," <i>Proc Natl Acad Sci</i> USA 94(2):10833-7, National Academy of Sciences (1997)			
	NPL132	Yamamoto, T., et al., "Ability of Oligonucleotides with Certain Palindromes to Induce Interferon Production and Augment Natural Killer Cell Activity is Associated with Their Base Length," Anti-sense Res Dev 4(2):119-22, Mary Ann Llebert Inc. (1994)			
	NPL133	Yamamoto, T., et al., "Synthetic oligonucleotides with certain palindromes stimulate interferon production of human peripheral blood lymphocytes in viltro," Jpn J Cancer Res 85(8):775-9, Japanese Cancer Association (1994)			

Examiner Signature Mosher/	Date Considered	04/07/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 38 USC. 122 and 37 CFR 1.14. This collection is settimated to take 2 mounts to complete, including gathering, preparing, and a counting the completed application form to the USPTO. Time will any depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent for Child Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commence, P.O. Box 1493, Alexandris V.A. 2231-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Olidei ii	ie r apei work	Reduction Act	or 1995, no persons are required in	b respond to a concentration of informa-	and the same and t	
				Complete If Known		
Substitute for	form 1449B/F	то		Application Number	10/551,054	
INFO	DRMAT	ION D	ISCLOSURE	Filing Date	§371 (c) Date: September 23, 2005	
STA	TEME	NT BY	APPLICANT	First Named Inventor	BACHMANN, Martin F.	
	(Use as n	nany sheets a	s necessary)	Art Unit	1648	
				Examiner Name	MOSHER, Mary	
Sheet	6	of	6	Attorney Docket Number	1700,0590000/BJD/WBC	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published				
	NPL134	Yu, D., et al., "Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties," Biochem Biophys Res Commun 297(1):83- 90, Academic Press (September 2002)				
-			_			

Examiner Signature /Mary Mosher/	Date Considered	04/07/2008

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optionan). *Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.97 and 1.98. The Information is required to obtain or A 19 the public which is to file and by the USPT 10 process) an application. Confidentiality is governed by \$5 U.S.C. 122 and 37 CFR 1.47 in its collection is estimated to late 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case Any comments on the amount of time by our require to complete this form anders suggestations for excluding this burder about the sent to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DESIDE TESS OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 4450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.